, but unlike JAK2V617F have never been reported in ET. Compared to PV patients with JAK2V617F, patients with exon 12 mutations have higher hemoglobin concentrations, lower white cell and platelet counts, and isolated bone marrow erythroid hyperplasia 1, 3 . Similar phenotypic differences were seen between retroviral murine bone marrow transplantation models carrying exon 12 mutant and V617F alleles 1 . These differences raise the question of how the signalling consequences of JAK2V617F and exon 12 mutations differ. Figure 1A ). This paired approach controls for factors including age, gender, treatment, germline genetic background and experimental conditions 7 . BFU-E colonies were cultured from peripheral blood as previously described 5 using 0.1U/ml erythropoietin (at which concentration We therefore focused on these two groups of patients to investigate the signalling differences responsible for these phenotypes. confirmed differential expression for all 11 genes ( Figure 1C) . Interestingly, when the expression changes in JAK2 exon 12-heterozygous colonies from six PV patients were compared with those in JAK2V617F-heterozygous colonies from six ET patients, there were no significant differences in the fold changes associated with the two mutation types, for any of these 11 genes ( Figure 1C , whilst absence of thrombocytosis in others may reflect STAT1-independent mechanisms such as accelerated platelet destruction 6 . Together our data support the concept that the development of a PV or ET phenotype reflects combinations of mechanisms operating differently between individuals, and moreover that these mechanisms differ between classes of JAK2 mutation.
1 associated with exon 12 mutations may reflect the strength of JAK2 activation is also consistent with evidence that JAK2V617F homozygosity results in a PV (rather than ET) phenotype 5, 6 . However the signalling consequences of exon 12-mutant JAK2 have not been examined in patient cells. Moreover the observations that JAK2V617F-heterozygous cells from PV patients show attenuated STAT1 activation compared to those with ET 7 , and that impaired STAT1 signalling can contribute to a PV phenotype 7, 8 , raise the question of whether reduced STAT1 activation is a feature of exon 12-mutated PV. We therefore studied the transcriptional signature of exon 12 mutations in erythroid colonies from PV patients.
Patients were recruited from seven centers (Supplementary Methods) and met British Committee for Standards in Haematology diagnostic criteria; for clinical features see Table 1 and Supplementary Table 1 . For 13 patients with JAK2 exon 12-mutated PV, we compared genome-wide RNA profiles of JAK2-mutant and wild-type erythroid colonies, grown from a single patient in the same culture plate ( Figure 1A ). This paired approach controls for factors including age, gender, treatment, germline genetic background and experimental conditions 7 . BFU-E colonies were cultured from peripheral blood as previously described 5 We therefore focused on these two groups of patients to investigate the signalling differences responsible for these phenotypes. We initially analysed Table 2 ). These findings demonstrate that the transcriptional changes associated with JAK2V617F and JAK2 exon 12 mutations in human erythroblasts are remarkably similar, with no quantitative or qualitative expression differences detected between the mutations in validation experiments.
We next investigated the pathways perturbed in JAK2 exon 12-mutant erythroid cells using Gene Set Enrichment Analysis (GSEA) 9 . Seventy-four gene sets showed enrichment in mutant samples and 83 gene sets in wildtype samples (q<0.1; Supplementary Table 3 Table 3 ), confirming that exon 12 and V617F mutations cause upregulation of similar pathways in erythroblasts.
The striking enrichment for IFN-related gene sets in JAK2 exon 12-mutant cells ( Figure 1D ) was of particular significance. JAK2 exon12 mutations are associated with an extreme PV phenotype (marked erythrocytosis, minimal thrombocytosis) 1, 3 . However we previously showed that JAK2V617F-mediated activation of STAT1, which is preserved in JAK2V617F-mutant erythroblasts of patients with ET, is impaired in those with JAK2V617F-positive PV 7 . Moreover functional experiments in human cells 7 and transgenic mice 8 suggested that attenuated activation of STAT1, which acts downstream of the IFNγ receptor and JAK2, might contribute to the more pronounced erythrocytosis in PV compared to ET. Upregulation of eight IFNγ-inducible Although fold changes were variable amongst the exon 12-mutant patients (perhaps reflecting signalling variation between different mutations), they were at least as large as in JAK2V617F-positive samples. These data demonstrate that interferon target genes are upregulated in JAK2 exon 12-heterozygous erythroblasts, to a similar extent as in JAK2V617F-heterozygous cells from ET patients.
We next asked whether upregulation of IFN target genes in JAK2 exon 12-mutant cells reflects STAT1 activation. Expression of either Jak2K539L or Jak2V617F in JAK2-null γ2A cells (Supplementary Methods) was associated with marked phospho-STAT1 activation compared to wild-type Jak2 ( Figure 2B ). To investigate whether STAT1 activation also occurs in human erythroid cells, erythroid colonies from three exon 12-mutated PV patients and two JAK2V617F-positive ET patients were analysed by intracellular flow cytometry (Supplementary Methods). All patients showed small but consistent increases in phospho-STAT5 and phospho-STAT1 expression in mutant compared to wild-type cells, which were similar in magnitude between JAK2 exon 12-mutated PV and JAK2V617F-positive ET samples ( Figure 2C ). The changes were modest, which is in keeping with previous studies using phosFlow to measure pSTAT changes in JAK2-mutant primary cells 12 shown, according to whether these were wild-type (WT), heterozygous (Het) or homozygous (Hom) for JAK2 exon 12 mutations. Where 2 samples were used for one genotype, these were independent pools of colonies collected from the same colony experiment. These pairs, and heterozygous-and homozygous-mutant sample pairs from the same patient, were treated as replicates in the analysis.
Samples from patients PX1, PX2, PX6, PX7, PX9 and PX10 were used for real-time PCR validation. B. Unsupervised hierarchical clustering of microarray datasets from wild-type and mutant colonies for 13 patients with JAK2 exon 12 mutations, performed using the lumi package in R. See Table 1 Table 3 ). These include gene sets upregulated by the stimulus that were enriched in mutant samples and gene sets downregulated by the stimulus that were enriched in wild-type samples. 
Supplementary information
Supplementary Of the JAK2 exon 12-mutant PV patients, six were used for real-time PCR analyses and three for intracellular flow cytometry. Of the JAK2V617F-positive ET patients, six were used for real-time PCR analyses and two for intracellular flow cytometry. 
Supplementary

Supplementary Methods
Patient recruitment
The study was approved by the Cambridge and Eastern Region Ethics Committee, patients gave written informed consent and research was carried out in accordance with the Declaration of Helsinki.
Patients were recruited from the following sites:
Addenbrooke's Hospital, Cambridge, UK 
RNA microarrays and data analysis
Individual BFU-E colonies were resuspended in RLT lysis buffer (Qiagen, Maryland, USA) and a portion used for DNA extraction and genotyping by direct sequencing 5 . Pools of approximately 20 colonies of the same genotype underwent RNA extraction (Qiagen RNeasy kit, Qiagen, Maryland, USA).
Quantification and RNA quality assessment (RIN values) were performed using an Agilent 2100 Bioanalyser (Agilent, Waldbronn, Germany). 50-100 ng total RNA were processed using the Illumina TotalPrep RNA amplification kit (Ambion, TX, USA), according to the manufacturer's instructions. Amplified cRNA was hybridised onto Illumina Human-12 v4.0 Expression BeadChips, chips were scanned using an Illumina BeadScanner, and fluorescence intensity data were extracted and quantified using Beadstudio.
Data were subjected to quality assessment, VST transformation and quantile normalisation using the lumi package in R. Datasets were filtered to include only probes that were expressed in over 50% of samples. Differential expression analyses were performed using the limma package in R 6 , with genotype and patient code incorporated into the contrast matrices so that corresponding wild-type and mutant samples from each patient were analysed in a pairwise fashion. For identification of differentially expressed genes, probes with a q value <0.1 (false discovery rate <10%) and a fold change of at least 1.25 between the two genotypes were selected.
Gene set enrichment analysis 4 was performed to analyse enrichment of gene sets for chemical and genetic perturbations (CGP), using GSEA software (http://www.broadinstitute.org/gsea/index.jsp). Analyses were performed using a pre-ranked list of genes according to T values from the limma analysis, according to the developer's protocol. FDR cut-off of 10% (q<0.1) was used.
Microarray data are available in the ArrayExpress database (www.ebi.ac.uk/arrayexpress) under accession number E-MTAB-3946.
Real-time PCR
Eleven genes were selected for validation based on possible roles in hematopoiesis, cell cycle or other processes relevant to neoplasia: ADA 7 
